Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab

被引：10
|
作者：
Korzenik, JR [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Internal Med, Gastrointestinal Unit, Boston, MA 02114 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2004年 / 33卷 / 02期
关键词：
D O I：
10.1016/j.gtc.2004.02.009
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The dramatic benefit experienced by many Crohn's patients treated with the anti-tumor necrosis factor-alpha (TNF-alpha) antibody infliximab underscores the centrality of this cytokine in the pathogenesis of Crohn's disease and the potential use of the therapeutic strategy of blocking TNF-alpha in this disease. In the hopes of emulating and improving on the success of infliximab, numerous strategies are being devised and studied to inhibit the actions of TNF-alpha. This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action.
引用
收藏
页码：285 / +
页数：18
相关论文
共 50 条
  • [41] A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease
    Papamichael, Konstantinos
    Mantzaris, Gerassimos J.
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 493 - 501
  • [42] Anti-Tumor Necrosis Factor Therapy to Prevent Crohn's Disease Recurrence After Surgery
    Herfarth, Hans H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1503 - 1506
  • [43] A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease
    Nie, Kai
    Zhang, Chao
    Deng, Minzi
    Luo, Weiwei
    Ma, Kejia
    Xu, Jiahao
    Wu, Xing
    Yang, Yuanyuan
    Wang, Xiaoyan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
    Ye, Byong Duk
    INTESTINAL RESEARCH, 2014, 12 (04) : 263 - 265
  • [45] Bronchoesophageal fistula in a patient with Crohn's disease receiving anti-tumor necrosis factor therapy
    Oh, Kyunghwan
    Choi, Kee Don
    Kim, Hyeong Ryul
    Shim, Tae Sun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Park, Sang Hyoung
    CLINICAL ENDOSCOPY, 2023, 56 (02) : 239 - 244
  • [46] The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn's Disease
    Kupcova, V.
    Turecky, L.
    Uhlikova, E.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (30) : 5226 - 5231
  • [47] Mycobacterium marinum infection in a patient with Crohn's disease on anti-tumor necrosis factor treatment
    Tooulia, Marilena
    Mellos, Aristotelis
    Vougadiotis, Ioannis
    Vrakas, Spyridon
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2024,
  • [48] Thromboembolic events and anti-tumor necrosis factor therapies
    Masson, P. L.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2012, 14 (04) : 444 - 445
  • [49] Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
    Kim, Hungdai
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (04) : 121 - 122
  • [50] Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: A case report
    Principi, M
    Di Leo, A
    Ingrosso, M
    Pisani, A
    Marangi, S
    Amoruso, A
    Panella, C
    Francavilla, A
    Ierardi, E
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2004, 26 (02) : 243 - 248
12345